Severe visual impairment or blindness at 6 to 12 months' corrected age · Prevention of retinopathy of prematurity in preterm infants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Rescue treatment with anti‐VEGF agents · Prevention of retinopathy of prematurity in preterm infants
Systemic administration of beta‐blockers may leads to lower rescue treatment with anti‐VEGF agents compared with placebo or no treatment (low certainty).
1 finding from 1 review
Treatment with laser photocoagulation or cryotherapy · Prevention of retinopathy of prematurity in preterm infants
Systemic administration of beta‐blockers may leads to lower treatment with laser photocoagulation or cryotherapy compared with placebo or no treatment (low certainty).
1 finding from 1 review
Progression to stage 2 with plus disease · Prevention of retinopathy of prematurity in preterm infants
Systemic administration of beta‐blockers showed no clear difference in progression to stage 2 with plus disease compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Progression to stage 3 ROP · Prevention of retinopathy of prematurity in preterm infants
Systemic administration of beta‐blockers probably leads to lower progression to stage 3 ROP compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Progression to stage 4 or 5 ROP · Prevention of retinopathy of prematurity in preterm infants
Systemic administration of beta‐blockers showed no clear difference in progression to stage 4 or 5 ROP compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Arterial hypotension and/or bradycardia requiring treatment · Prevention of retinopathy of prematurity in preterm infants
Systemic administration of beta‐blockers may leads to higher arterial hypotension and/or bradycardia requiring treatment compared with placebo or no treatment (low certainty).
1 finding from 1 review
Proportion of participants attending screening (median · patients with type 1 or 2 diabetes eligible for diabetic retinopathy screening
1 finding from 1 review
Ongoing adherence to screening · patients with type 1 or 2 diabetes eligible for diabetic retinopathy screening
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Economic Outcomes Resources used (staff time, equipment, consumables) · patients with type 1 or 2 diabetes eligible for diabetic retinopathy screening
1 finding from 1 review
Staff/personnel costs; costs of treatment and care; cost of primary care; lost wages and lost productivity · patients with type 1 or 2 diabetes eligible for diabetic retinopathy screening
1 finding from 1 review
Incremental cost‐effectiveness · patients with type 1 or 2 diabetes eligible for diabetic retinopathy screening
1 finding from 1 review
Proportion of participants attending screening (median · patients with type 1 or 2 diabetes eligible for diabetic retinopathy screening
1 finding from 1 review
Ongoing adherence to screening · patients with type 1 or 2 diabetes eligible for diabetic retinopathy screening
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Economic outcomes · patients with type 1 or 2 diabetes eligible for diabetic retinopathy screening
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
BCVA: loss of 15 or more ETDRS letters · proliferative diabetic retinopathy
It is very uncertain whether nd:YAG laser changes BCVA: loss of 15 or more ETDRS letters compared with argon‐green laser (very low certainty).
1 finding from 1 review
Progression of PDR · proliferative diabetic retinopathy
It is very uncertain whether diode laser changes progression of PDR compared with argon laser (very low certainty).
1 finding from 1 review
Regression of PDR · proliferative diabetic retinopathy
It is very uncertain whether diode laser changes regression of PDR compared with argon laser (very low certainty).
1 finding from 1 review
Pain during laser treatment ‐ not reported · proliferative diabetic retinopathy
Diode laser probably leads to higher pain during laser treatment compared with argon laser (moderate certainty).
1 finding from 1 review
Vision‐related QoL ‐ not reported · proliferative diabetic retinopathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found